By Fineline Cube Merck & Co., Inc. (MSD, NYSE: MRK) and Eisai Co., Ltd. (TYO: 4523) announced that the Phase III LITESPARK-012 study did not achieve its co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in patients with first-line advanced clear cell renal cell carcinoma (RCC).
Trial Design & Results Summary
| Comparison Arm | Regimen Evaluated | Outcome |
|---|---|---|
| Arm A | Pembrolizumab + Lenvatinib + Belzutifan vs. Pembrolizumab + Lenvatinib | Did not meet PFS or OS endpoints |
| Arm B | MK-1308A + Lenvatinib vs. Pembrolizumab + Lenvatinib | Did not meet PFS or OS endpoints |
The study evaluated two novel combination approaches against the current standard of care (pembrolizumab + lenvatinib), which is already approved in the U.S., EU, Japan, and other regions for first-line advanced RCC treatment.
Drug Portfolio Context
- MK-1308A: Novel combination of MK-1308 (anti-CTLA-4 antibody in-licensed from China-based Akeso, Inc.) and Merck’s PD-1 inhibitor Keytruda (pembrolizumab)
- Belzutifan: HIF-2α inhibitor previously approved for certain VHL-associated tumors
- Current Standard: Pembrolizumab + lenvatinib remains the approved first-line regimen for advanced RCC
Strategic Implications
The negative results represent a setback in efforts to improve upon the established pembrolizumab-lenvatinib combination, which generated approximately $2.8 billion in global sales in 2025. Both companies indicated they will conduct comprehensive analyses of the full dataset to inform future development strategies in renal cell carcinoma.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical trial results and development plans. Actual outcomes may differ based on final data analyses, regulatory decisions, and competitive developments in the oncology landscape.-Fineline Info & Tech